feed,title,long_url,short_url
Benzinga,Veru Shares Jump Over 40% Despite FDA Staff Raises Uncertainties Over Its COVID-19 Therapy,https://benzinga.com/general/biotech/22/11/29598538/veru-shares-jump-over-40-despite-fda-staff-raises-uncertainties-over-its-covid-19-therapy,https://bit.ly/3NIlA9Q
Benzinga,Beam Therapeutics Temporarily Retreats Clinical Plans For Second Sickle Cell Gene Therapy,https://benzinga.com/general/biotech/22/11/29597874/beam-therapeutics-temporarily-retreats-clinical-plans-for-second-sickle-cell-gene-therapy,https://bit.ly/3FQ8wgF
